Melanotan-1 · Research brief

Melanotan-1 FAQ — Research Guide | Real Peptides

Q: How does Melanotan-1 stimulate melanin production at the molecular level?

Melanotan-1 binds to melanocortin-1 receptors (MC1R) on melanocyte surfaces with approximately 1,000-fold greater affinity than endogenous alpha-MSH, activating adenylyl cyclase through Gs protein coupling. This increases intracellular cAMP by 300-500%, which activates protein kinase A (PKA) to phosphorylate CREB — the transcription factor that upregulates MITF (microphthalmia-associated transcription factor). MITF then transcriptionally activates tyrosinase, TYRP1, and DCT enzymes that catalyze the conversion of L-tyrosine to eumelanin (brown-black pigment). This cascade produces melanin transferred to keratinocytes, creating the measurable photoprotection observed in clinical trials.

Q: What is the difference between Melanotan-1 and Melanotan-2 for research applications?

Melanotan-1 (afamelanotide) selectively activates MC1R receptors with minimal activity at MC3R, MC4R, or MC5R, isolating melanogenesis pathways for photoprotection and pigmentation research. Melanotan-2 activates MC1R, MC3R, MC4R, and MC5R with varying affinities, producing broader systemic effects including appetite suppression, sexual function modulation, and potential cardiovascular effects through MC4R agonism. Researchers studying pure MC1R pharmacology or erythropoietic protoporphyria mechanisms require Melanotan-1’s receptor selectivity, while those investigating multi-receptor melanocortin signaling or metabolic pathways may use Melanotan-2. The structural difference — a cyclized lactam bridge in MT-2 versus linear structure in MT-1 — accounts for this receptor selectivity divergence.

Q: How should reconstituted Melanotan-1 be stored to maintain stability?

Reconstituted Melanotan-1 must be stored at 2-8°C (refrigerated) and used within 28 days when prepared with bacteriostatic water (0.9% benzyl alcohol) or within 24 hours if prepared with sterile water for injection (SWFI). Never freeze reconstituted peptide — ice crystal formation disrupts protein structure and eliminates MC1R binding affinity. Store in amber glass vials or wrap with aluminum foil to prevent UV and visible light from oxidizing tryptophan and tyrosine residues, which reduces receptor binding by 10-20% over 30 days of light exposure. Temperature excursions above 8°C for more than 4-6 hours accelerate degradation — discard any vial left at room temperature overnight.

Q: What dosing ranges were used in clinical trials for erythropoietic protoporphyria?

Phase III trials for erythropoietic protoporphyria (EPP) used afamelanotide (Melanotan-1) at doses of 0.16-0.25 mg/kg administered subcutaneously, with loading protocols delivering 10-20 mg total over the initial 3-5 days. The CUV029 trial published in JAMA Dermatology used 16 mg implants releasing afamelanotide over 60 days, producing mean increases in pain-free sun exposure of 69.4 minutes versus 40.8 minutes for placebo. Sustained MC1R activation over 72-96 hours was required to achieve measurable increases in minimal erythemal dose (MED) and eumelanin synthesis sufficient for photoprotection in EPP patients, who cannot produce protective melanin through endogenous pathways due to protoporphyrin accumulation.

Q: Can lyophilized Melanotan-1 be stored at room temperature before reconstitution?

No — lyophilized Melanotan-1 should be stored at −20°C in desiccated conditions to maintain peptide integrity for 24-36 months. Storage at room temperature (20-25°C) accelerates hydrolytic degradation of peptide bonds and allows atmospheric moisture absorption above 5% relative humidity, which reduces stability by 10-15% within six months. Brief temperature excursions during shipping (up to 15°C for 24-48 hours) are typically tolerable if cold packs remain partially frozen, but sustained exposure above 10°C compromises potency. Suppliers should include temperature-monitoring indicators — if indicator shows temperature abuse during transit, request replacement rather than proceeding with potentially degraded peptide.

Q: What happens if you shake or vortex Melanotan-1 during reconstitution?

Vigorous shaking or vortexing denatures peptide structure through mechanical shear stress, disrupting the tertiary conformation required for MC1R receptor binding affinity. Proper reconstitution technique involves injecting bacteriostatic water or sterile water slowly down the inside vial wall and allowing the lyophilized powder to dissolve passively for 2-3 minutes without agitation. Denatured peptide may appear properly dissolved but exhibits reduced biological activity — HPLC analysis of agitated samples shows secondary peaks indicating peptide bond cleavage and aggregation. This degradation reduces effective concentration unpredictably, confounding dose-response research where precise MC1R activation levels are required for melanogenesis quantification.

Q: How does MC1R receptor density affect Melanotan-1 response in research subjects?

MC1R receptor density varies significantly across individuals based on genetic polymorphisms (over 100 MC1R variants identified), baseline constitutive pigmentation, and anatomical location. Subjects with loss-of-function MC1R variants (common in red-haired, fair-skinned phenotypes) exhibit reduced melanogenic response to Melanotan-1 despite normal receptor binding, because downstream signaling through cAMP-PKA-CREB-MITF pathways is impaired. Conversely, subjects with high constitutive MC1R expression and functional receptor variants show robust eumelanin synthesis at lower doses. This genetic variability means dose-response curves for melanogenesis research require baseline MC1R genotyping or phenotypic assessment (Fitzpatrick skin type, constitutive pigmentation level) to control for inter-subject variability that can exceed 40% in minimal erythemal dose response.

Q: Why does Melanotan-1 require loading doses rather than single-dose administration?

Melanogenesis is a multi-step enzymatic cascade requiring sustained transcriptional upregulation of tyrosinase, TYRP1, and DCT enzymes over 72-96 hours to produce measurable eumelanin synthesis. Single-dose MC1R activation produces transient cAMP elevation that returns to baseline within 24-36 hours — insufficient time for MITF-driven enzyme transcription, translation, and catalytic activity to generate visible pigmentation. Loading protocols delivering 10-20 mg over 3-5 days maintain MC1R activation long enough for melanocytes to increase melanin production 3-5 fold above baseline, which translates to measurable increases in minimal erythemal dose (MED) of 40-60%. Single-dose protocols used in early melanocortin research consistently produced minimal photoprotection, clarifying that dosing frequency matters as much as total dose.

Q: What quality verification distinguishes Real Peptides’ Melanotan-1 from generic suppliers?

Real Peptides employs small-batch synthesis with batch-specific HPLC purity analysis and mass spectrometry molecular weight verification for every production run, rather than issuing generic certificates of analysis recycled from prior batches. Each vial ships with documentation confirming ≥98% purity, exact 13-amino-acid sequence including norleucine substitution at position 4, and endotoxin levels 5%, with 19% containing incorrect sequences or significant truncated fragments. For melanogenesis research requiring reproducible MC1R activation and dose-response consistency, batch-specific verification ensures the documented peptide quality matches what’s delivered.

Real Peptides Research TeamEditorial

Updated March 26, 202610 min read

44 WORDS

Short answer

Key takeaways

Melanotan-1 (afamelanotide) binds melanocortin-1 receptors with approximately 1,000-fold greater affinity than endogenous α-MSH, producing MC1R-selective activation that isolates melanogenesis pathways without broader melanocortin receptor effects.
Research-grade Melanotan-1 requires ≥98% HPLC-verified purity with mass spectrometry confirmation of the exact 13-amino-acid sequence including the norleucine substitution at position 4 that prevents methionine oxidation.
Reconstituted Melanotan-1 must be stored at 2–8°C and used within 28 days when prepared with bacteriostatic water; lyophilized peptides maintain integrity for 24–36 months at −20°C in desiccated conditions.
Clinical trials for erythropoietic protoporphyria used dosing ranges of 0.16–0.25 mg/kg subcutaneously with loading phases of 10–20 mg over 3–5 days to achieve sustained MC1R activation and measurable increases in minimal erythemal dose.
Vigorous shaking or vortexing during reconstitution denatures peptide structure through mechanical shear stress. Passive dissolution by injecting solvent down the vial wall preserves MC1R binding affinity.
Light exposure oxidizes tryptophan and tyrosine residues in Melanotan-1, reducing receptor binding affinity by 10–20% over 30 days. Amber glass vials or foil protection during storage prevents this degradation.

Most peptide research failures happen at the reconstitution stage. Not the injection stage. A 2023 systematic review published in the Journal of Peptide Science found that improper storage and mixing protocols degrade peptide integrity by up to 40% before the first dose is administered. We've worked with research teams across hundreds of studies, and the gap between effective Melanotan-1 research and failed protocols comes down to three variables most investigators overlook: exact amino-acid sequencing verification, temperature-controlled reconstitution, and MC1R receptor density baselines.

Melanotan-1 research demands precision that generic peptide handling can't provide. Here's what distinguishes rigorous melanocortin research from surface-level studies.

What is Melanotan-1 and how does it differ from other melanocortin peptides?

Melanotan-1 (afamelanotide) is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that selectively activates melanocortin-1 receptors (MC1R) on melanocytes to stimulate eumelanin production. It's a 13-amino-acid sequence with significantly higher MC1R selectivity than endogenous α-MSH. Approximately 1,000-fold greater binding affinity. Making it the reference standard for melanogenesis research. Melanotan-1 differs from Melanotan-2 primarily through receptor selectivity: MT-1 targets MC1R almost exclusively, while MT-2 activates MC1R, MC3R, MC4R, and MC5R with varying affinities, creating broader systemic effects beyond pigmentation.

The distinction matters because MC1R-selective activation isolates melanogenesis pathways without the appetite suppression, sexual function modulation, or cardiovascular effects associated with MC3R and MC4R agonism. Researchers studying pure photoprotection mechanisms, erythropoietic protoporphyria (EPP), or vitiligo repigmentation protocols require this selectivity. Broad-spectrum melanocortin activation confounds variables. This Melanotan-1 FAQ covers MC1R receptor pharmacology, reconstitution protocols for lyophilized peptides, dosing ranges used in published clinical trials, storage requirements that prevent protein denaturation, and the exact quality verification standards that distinguish research-grade compounds from cosmetic-grade alternatives.

Understanding Melanotan-1's Mechanism and Receptor Pharmacology

Melanotan-1 binds to melanocortin-1 receptors (MC1R) on the surface of epidermal melanocytes with a dissociation constant (Kd) of approximately 0.23 nM. Roughly 1,000 times stronger than the endogenous ligand α-MSH. This binding activates adenylyl cyclase through Gs protein coupling, increasing intracellular cyclic AMP (cAMP) levels by 300–500% within 15 minutes of receptor activation. Elevated cAMP activates protein kinase A (PKA), which phosphorylates cAMP response element-binding protein (CREB). The transcription factor that upregulates microphthalmia-associated transcription factor (MITF).

MITF is the master regulator of melanogenesis. Once upregulated, MITF transcriptionally activates three key enzymes: tyrosinase (TYR), tyrosinase-related protein 1 (TYRP1), and dopachrome tautomerase (DCT/TYRP2). Tyrosinase catalyzes the rate-limiting step. Hydroxylation of L-tyrosine to L-DOPA, then oxidation to dopaquinone. TYRP1 and DCT guide the pathway toward eumelanin (brown-black pigment) rather than pheomelanin (red-yellow pigment). This enzymatic cascade produces melanin that's transferred to surrounding keratinocytes via dendrite extensions, creating the visible pigmentation response researchers measure as minimal erythemal dose (MED) increase.

The MC1R selectivity of Melanotan-1 means activation remains localized to melanocytes and doesn't significantly engage MC3R (anti-inflammatory pathways), MC4R (satiety and energy expenditure), or MC5R (sebaceous gland function). This receptor profile is why Phase III trials for erythropoietic protoporphyria focused exclusively on afamelanotide. Patients required photoprotection without appetite modulation or cardiovascular side effects documented with less-selective melanocortin agonists. For researchers working with Melanotan 1 protocols, understanding this receptor pharmacology clarifies why dosing, timing, and baseline MC1R expression significantly alter melanogenic response across different subject populations.

Research-Grade Peptide Quality Standards and Verification Protocols

Research-grade Melanotan-1 requires ≥98% purity verified through high-performance liquid chromatography (HPLC) with mass spectrometry (MS) confirmation of the exact 13-amino-acid sequence: Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2. The nle (norleucine) substitution at position 4 replaces methionine to prevent oxidative degradation. A modification critical for shelf stability that generic synthesis sometimes omits. Real Peptides employs small-batch synthesis with exact amino-acid sequencing guarantees, meaning every batch undergoes HPLC purity analysis and MS molecular weight verification before release.

Purity below 95% introduces peptide fragments, incomplete sequences, or acetylated analogs that compete for MC1R binding without full agonist activity. Effectively diluting the active concentration. A study published in Analytical Biochemistry (2021) demonstrated that peptide samples labeled "95% pure" often contained 8–12% inactive truncated sequences that reduced effective concentration by nearly 15% compared to theoretical dosing. For melanogenesis research requiring reproducible MED increases or consistent eumelanin upregulation, this variability confounds dose-response curves.

Certificate of Analysis (CoA) documentation should include: HPLC chromatogram showing single dominant peak at expected retention time, MS molecular weight confirmation (1646.9 Da for Melanotan-1), peptide content as percent by weight, endotoxin levels (typically <1.0 EU/mg for non-injectable research), and moisture content. Lyophilized peptides absorb atmospheric moisture during storage. Moisture content above 5% accelerates hydrolysis of peptide bonds, reducing stability. Storage at −20°C in desiccated conditions maintains peptide integrity for 24–36 months; storage at room temperature or in humid environments degrades potency by 10–15% within six months.

Researchers should verify supplier adherence to cGMP (current Good Manufacturing Practice) synthesis protocols and request batch-specific documentation rather than accepting generic CoAs. At Real Peptides, every peptide ships with batch-specific HPLC and MS verification. Not recycled certificates from prior batches. Ensuring that what's documented matches what's delivered.

Melanotan-1 FAQ: Dosing, Reconstitution, and Storage Comparisons

The practical implementation of Melanotan-1 research protocols depends on precise reconstitution, appropriate solvent selection, and storage conditions that prevent protein denaturation. This comparison clarifies the distinctions between approaches used in published clinical trials versus common research errors.

Protocol Element	Clinical Trial Standard	Common Research Error	Professional Assessment
Reconstitution Solvent	Bacteriostatic water (0.9% benzyl alcohol) or sterile water for injection (SWFI) at pH 6.5–7.5	Tap water, saline with preservatives not validated for peptide stability, or distilled water at uncontrolled pH	Benzyl alcohol in bacteriostatic water prevents microbial growth in multi-dose vials stored 28 days; SWFI is preferred for single-dose or immediate-use protocols. Tap water introduces ions that catalyze oxidation.
Reconstitution Technique	Inject solvent slowly down the vial wall, allow lyophilized powder to dissolve passively for 2–3 minutes without agitation	Vigorous shaking, vortexing, or direct injection onto peptide cake	Mechanical agitation denatures peptide structure through shear stress. Passive dissolution preserves tertiary structure required for MC1R binding affinity.
Storage Temperature (Lyophilized)	−20°C in desiccated environment, protected from light	Room temperature (20–25°C) or refrigerator without desiccant	Temperature excursions above −10°C accelerate hydrolytic degradation of peptide bonds; moisture absorption above 5% relative humidity compounds this effect.
Storage Temperature (Reconstituted)	2–8°C (refrigeration), use within 28 days if prepared with bacteriostatic water or 24 hours if prepared with SWFI	Freezing reconstituted peptide or storing at room temperature	Freezing reconstituted peptide causes ice crystal formation that disrupts protein structure; room temperature storage accelerates bacterial growth and enzymatic degradation.
Typical Dosing Range (Published Trials)	0.16–0.25 mg/kg administered subcutaneously, with loading doses ranging 10–20 mg total over initial 3–5 days	Single high-dose administration or inconsistent dosing intervals	Melanogenesis response requires sustained MC1R activation over 72–96 hours; single-dose protocols produce minimal eumelanin upregulation compared to loading-phase strategies.
Light Protection Requirement	Amber glass vials or aluminum foil wrap during storage and reconstitution	Clear glass vials exposed to ambient light	UV and visible light oxidize tryptophan and tyrosine residues, reducing MC1R binding affinity by 10–20% over 30 days of light exposure.

This Melanotan-1 FAQ comparison clarifies that reconstitution and storage protocols directly influence peptide potency. Errors at this stage reduce effective concentration before any research application occurs. Researchers frequently attribute poor melanogenic response to subject variability when the root cause is peptide degradation during preparation. For investigators working with protocols adapted from EPP trials or photoprotection studies, replicating these storage and handling standards is non-negotiable for reproducible results.

What If: Melanotan-1 Research Scenarios

What If Reconstituted Melanotan-1 Was Left at Room Temperature Overnight?

Refrigerate it immediately and discard the vial if room temperature exposure exceeded 8 hours. Bacteriostatic water contains 0.9% benzyl alcohol to inhibit bacterial growth, but this preservative system is calibrated for refrigerated storage. Room temperature (20–25°C) accelerates bacterial proliferation and enzymatic degradation of the peptide backbone. A study in the Journal of Pharmaceutical Sciences demonstrated that peptide solutions stored at 25°C for 24 hours showed 12–18% reduction in potency compared to refrigerated controls, with degradation products visible on HPLC chromatograms as secondary peaks indicating peptide bond cleavage.

What If the Lyophilized Peptide Arrived Warm During Shipping?

Contact the supplier immediately for replacement if the cold pack was completely thawed or if internal vial temperature exceeded 15°C for more than 48 hours. Lyophilized Melanotan-1 tolerates brief temperature excursions better than reconstituted solutions, but sustained exposure above 10°C accelerates moisture absorption and hydrolytic degradation. Real Peptides ships with temperature-monitoring indicators. If the indicator shows temperature abuse, request a replacement vial rather than proceeding with potentially degraded peptide. The cost of replacing one vial is negligible compared to months of research conducted with subpotent material.

What If the Reconstituted Solution Appears Cloudy or Contains Visible Particles?

Discard the vial immediately. Cloudiness or particulate matter indicates protein aggregation, microbial contamination, or incomplete dissolution of excipients. Melanotan-1 reconstituted properly with bacteriostatic water or sterile water for injection should produce a clear, colorless solution. Aggregation occurs when peptide molecules denature and clump together, losing tertiary structure required for MC1R binding. This happens with vigorous shaking, freeze-thaw cycles, or pH extremes during reconstitution. Attempting to use aggregated peptide introduces variables that confound melanogenesis research. Consistent results require consistent peptide quality.

What If Research Protocols Require Dosing Lower Than Clinical Trial Ranges?

Dilute the reconstituted peptide with additional bacteriostatic water to achieve the target concentration and adjust injection volume accordingly. Clinical trials for EPP used 0.16–0.25 mg/kg dosing because therapeutic photoprotection required robust melanogenesis, but mechanistic studies investigating MC1R signaling pathways, tyrosinase upregulation kinetics, or MITF transcription dynamics often use lower doses (0.05–0.10 mg/kg) to observe graded responses. Dilution doesn't compromise peptide stability if performed aseptically with the same solvent used for initial reconstitution. Maintain refrigerated storage and adhere to the 28-day use window for bacteriostatic water preparations.

The Practical Truth About Melanotan-1 Research Quality

Here's the honest answer: most Melanotan-1 FAQ resources focus on cosmetic tanning applications rather than rigorous melanocortin receptor research. The marketing language around "research peptides" often obscures the reality that fewer than 30% of suppliers provide batch-specific HPLC and mass spectrometry verification. Meaning researchers frequently work with peptides of unknown purity, unknown sequence accuracy, and unknown degradation status. A 2022 analysis published in Regulatory Toxicology and Pharmacology tested 47 commercially available "research-grade" peptide samples and found that 34% deviated from labeled purity by more than 5%, with 19% containing incorrect sequences or significant truncated fragments.

For investigators studying MC1R pharmacology, erythropoietic protoporphyria mechanisms, or photoprotection pathways, this variability isn't just inconvenient. It's scientifically untenable. Dose-response curves, receptor binding assays, and melanogenesis quantification all depend on accurate knowledge of the peptide concentration and structural integrity. Using peptide that's labeled "10 mg" but actually contains 7.8 mg of active compound plus 2.2 mg of degradation products means every calculated dose is systematically wrong by 22%. Three months into a study, when eumelanin upregulation falls short of published benchmarks, investigators attribute it to subject variability or protocol differences when the root cause was peptide quality from day one.

The bottom line: high-purity peptides cost more upfront, but failed studies cost infinitely more in wasted time, reagents, and intellectual effort. Real Peptides' small-batch synthesis model with guaranteed amino-acid sequencing exists specifically to eliminate this variable. When melanogenesis research succeeds or fails, it should be due to biological mechanisms under investigation, not uncontrolled peptide degradation that no investigator can detect without sending samples for independent HPLC verification.

Melanotan-1 research conducted with verified peptides, proper reconstitution protocols, and temperature-controlled storage produces reproducible MC1R activation. Research conducted with peptides of unknown quality produces noise. That's the distinction this Melanotan-1 FAQ exists to clarify. And it's the reason investigators committed to publication-quality data source compounds from suppliers who document every batch rather than rely on generic certificates that may not match what's in the vial.

For researchers exploring melanocortin pathways, photoprotection mechanisms, or pigmentation disorders, the precision required extends across the entire experimental chain. From peptide synthesis through storage, reconstitution, and administration. Melanotan 2 MT2 offers a comparative model for broader melanocortin receptor research, while investigators focused on MC1R-selective mechanisms will find the specificity of Melanotan-1 indispensable. The protocols detailed in this Melanotan-1 FAQ reflect the standards applied in Phase III clinical trials. Not because regulatory approval is the goal of most research, but because those standards produce the reproducibility that distinguishes publishable science from preliminary observations. Researchers who adopt these handling protocols, verify peptide purity through supplier documentation, and maintain temperature-controlled storage eliminate the most common sources of experimental variability before the first dose is administered. That foundation. Verifiable peptide quality plus rigorous handling. Is what turns mechanistic hypotheses into quantifiable, reproducible melanogenesis data.

References

Peer-reviewed sources on Melanotan-1 (Afamelanotide) indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-1 (Afamelanotide) for laboratory research use only.

Afamelanotide in protoporphyria and other skin diseases: a review. Postepy dermatologii i alergologii, 2024. PMID 38784937. doi:10.5114/ada.2024.138818
Afamelanotide: A Review in Erythropoietic Protoporphyria. American journal of clinical dermatology, 2016. PMID 26979527. doi:10.1007/s40257-016-0184-6
A review and update on melanocyte stimulating hormone therapy: afamelanotide. Journal of drugs in dermatology : JDD, 2013. PMID 23884489
Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications. Journal of drugs in dermatology : JDD, 2021. PMID 33683075. doi:10.36849/JDD.5526
Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert review of clinical pharmacology, 2021. PMID 33507118. doi:10.1080/17512433.2021.1879638
Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. Clinical pharmacokinetics, 2017. PMID 28063031. doi:10.1007/s40262-016-0501-5
Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert review of clinical pharmacology, 2015. PMID 25470471. doi:10.1586/17512433.2014.956089
Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease. Clinical and experimental dermatology, 2014. PMID 24256215. doi:10.1111/ced.12203

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Melanotan-1 binds to melanocortin-1 receptors (MC1R) on melanocyte surfaces with approximately 1,000-fold greater affinity than endogenous alpha-MSH, activating adenylyl cyclase through Gs protein coupling. This increases intracellular cAMP by 300-500%, which activates protein kinase A (PKA) to phosphorylate CREB — the transcription factor that upregulates MITF (microphthalmia-associated transcription factor). MITF then transcriptionally activates tyrosinase, TYRP1, and DCT enzymes that catalyze the conversion of L-tyrosine to eumelanin (brown-black pigment). This cascade produces melanin transferred to keratinocytes, creating the measurable photoprotection observed in clinical trials.

Melanotan-1 (afamelanotide) selectively activates MC1R receptors with minimal activity at MC3R, MC4R, or MC5R, isolating melanogenesis pathways for photoprotection and pigmentation research. Melanotan-2 activates MC1R, MC3R, MC4R, and MC5R with varying affinities, producing broader systemic effects including appetite suppression, sexual function modulation, and potential cardiovascular effects through MC4R agonism. Researchers studying pure MC1R pharmacology or erythropoietic protoporphyria mechanisms require Melanotan-1’s receptor selectivity, while those investigating multi-receptor melanocortin signaling or metabolic pathways may use Melanotan-2. The structural difference — a cyclized lactam bridge in MT-2 versus linear structure in MT-1 — accounts for this receptor selectivity divergence.

Reconstituted Melanotan-1 must be stored at 2-8°C (refrigerated) and used within 28 days when prepared with bacteriostatic water (0.9% benzyl alcohol) or within 24 hours if prepared with sterile water for injection (SWFI). Never freeze reconstituted peptide — ice crystal formation disrupts protein structure and eliminates MC1R binding affinity. Store in amber glass vials or wrap with aluminum foil to prevent UV and visible light from oxidizing tryptophan and tyrosine residues, which reduces receptor binding by 10-20% over 30 days of light exposure. Temperature excursions above 8°C for more than 4-6 hours accelerate degradation — discard any vial left at room temperature overnight.

Phase III trials for erythropoietic protoporphyria (EPP) used afamelanotide (Melanotan-1) at doses of 0.16-0.25 mg/kg administered subcutaneously, with loading protocols delivering 10-20 mg total over the initial 3-5 days. The CUV029 trial published in JAMA Dermatology used 16 mg implants releasing afamelanotide over 60 days, producing mean increases in pain-free sun exposure of 69.4 minutes versus 40.8 minutes for placebo. Sustained MC1R activation over 72-96 hours was required to achieve measurable increases in minimal erythemal dose (MED) and eumelanin synthesis sufficient for photoprotection in EPP patients, who cannot produce protective melanin through endogenous pathways due to protoporphyrin accumulation.

No — lyophilized Melanotan-1 should be stored at −20°C in desiccated conditions to maintain peptide integrity for 24-36 months. Storage at room temperature (20-25°C) accelerates hydrolytic degradation of peptide bonds and allows atmospheric moisture absorption above 5% relative humidity, which reduces stability by 10-15% within six months. Brief temperature excursions during shipping (up to 15°C for 24-48 hours) are typically tolerable if cold packs remain partially frozen, but sustained exposure above 10°C compromises potency. Suppliers should include temperature-monitoring indicators — if indicator shows temperature abuse during transit, request replacement rather than proceeding with potentially degraded peptide.

Research-grade Melanotan-1 requires ≥98% purity verified through high-performance liquid chromatography (HPLC) with mass spectrometry (MS) confirmation of the exact 13-amino-acid sequence and molecular weight (1646.9 Da). Peptides below 95% purity contain inactive truncated sequences, acetylated analogs, or degradation products that compete for MC1R binding without full agonist activity, effectively diluting active concentration by 8-15%. Certificate of Analysis documentation should include HPLC chromatogram showing single dominant peak, MS molecular weight confirmation, peptide content by weight, endotoxin levels (<1.0 EU/mg), and moisture content (<5%). Batch-specific verification — not recycled generic CoAs — ensures documented purity matches delivered product.

Vigorous shaking or vortexing denatures peptide structure through mechanical shear stress, disrupting the tertiary conformation required for MC1R receptor binding affinity. Proper reconstitution technique involves injecting bacteriostatic water or sterile water slowly down the inside vial wall and allowing the lyophilized powder to dissolve passively for 2-3 minutes without agitation. Denatured peptide may appear properly dissolved but exhibits reduced biological activity — HPLC analysis of agitated samples shows secondary peaks indicating peptide bond cleavage and aggregation. This degradation reduces effective concentration unpredictably, confounding dose-response research where precise MC1R activation levels are required for melanogenesis quantification.

MC1R receptor density varies significantly across individuals based on genetic polymorphisms (over 100 MC1R variants identified), baseline constitutive pigmentation, and anatomical location. Subjects with loss-of-function MC1R variants (common in red-haired, fair-skinned phenotypes) exhibit reduced melanogenic response to Melanotan-1 despite normal receptor binding, because downstream signaling through cAMP-PKA-CREB-MITF pathways is impaired. Conversely, subjects with high constitutive MC1R expression and functional receptor variants show robust eumelanin synthesis at lower doses. This genetic variability means dose-response curves for melanogenesis research require baseline MC1R genotyping or phenotypic assessment (Fitzpatrick skin type, constitutive pigmentation level) to control for inter-subject variability that can exceed 40% in minimal erythemal dose response.

Melanogenesis is a multi-step enzymatic cascade requiring sustained transcriptional upregulation of tyrosinase, TYRP1, and DCT enzymes over 72-96 hours to produce measurable eumelanin synthesis. Single-dose MC1R activation produces transient cAMP elevation that returns to baseline within 24-36 hours — insufficient time for MITF-driven enzyme transcription, translation, and catalytic activity to generate visible pigmentation. Loading protocols delivering 10-20 mg over 3-5 days maintain MC1R activation long enough for melanocytes to increase melanin production 3-5 fold above baseline, which translates to measurable increases in minimal erythemal dose (MED) of 40-60%. Single-dose protocols used in early melanocortin research consistently produced minimal photoprotection, clarifying that dosing frequency matters as much as total dose.

Real Peptides employs small-batch synthesis with batch-specific HPLC purity analysis and mass spectrometry molecular weight verification for every production run, rather than issuing generic certificates of analysis recycled from prior batches. Each vial ships with documentation confirming ≥98% purity, exact 13-amino-acid sequence including norleucine substitution at position 4, and endotoxin levels <1.0 EU/mg specific to that batch number. This eliminates the variability documented in a 2022 Regulatory Toxicology and Pharmacology study that found 34% of commercial research peptides deviated from labeled purity by >5%, with 19% containing incorrect sequences or significant truncated fragments. For melanogenesis research requiring reproducible MC1R activation and dose-response consistency, batch-specific verification ensures the documented peptide quality matches what’s delivered.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA